Your browser doesn't support javascript.
loading
Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
Kyvernitakis, Ioannis; Kann, Peter Herbert; Thomasius, Friederike; Hars, Olaf; Hadji, Peyman.
Afiliação
  • Kyvernitakis I; Department of Obstetrics and Gynecology, Buergerhospital Frankfurt, Dr. Senckenberg Foundation and Goethe-University of Frankfurt, Germany; Faculty of Medicine, Philipps-University of Marburg, Germany. Electronic address: janniskyvernitakis@gmail.com.
  • Kann PH; Division of Endocrinology, Diabetology and Osteology, Philipps-University of Marburg, Germany.
  • Thomasius F; Department of Bone Oncology, gyn. Endocrinology and Reproductive Medicine, Nordwest Hospital, Frankfurt, Germany.
  • Hars O; Statistical Institute Berlin, Germany.
  • Hadji P; Faculty of Medicine, Philipps-University of Marburg, Germany; Department of Bone Oncology, gyn. Endocrinology and Reproductive Medicine, Nordwest Hospital, Frankfurt, Germany.
Bone ; 114: 109-115, 2018 09.
Article em En | MEDLINE | ID: mdl-29908297

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reabsorção Óssea / Neoplasias da Mama / Pré-Menopausa / Conservadores da Densidade Óssea / Ácido Zoledrônico / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Bone Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reabsorção Óssea / Neoplasias da Mama / Pré-Menopausa / Conservadores da Densidade Óssea / Ácido Zoledrônico / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Bone Ano de publicação: 2018 Tipo de documento: Article